• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Relationship between serum ferritin and growth status of pediatric transfusion dependent thalassemia.血清铁蛋白与小儿输血依赖型地中海贫血生长状态的关系
Caspian J Intern Med. 2023 Summer;14(3):425-432. doi: 10.22088/cjim.14.3.425.
2
Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study.口服螯合剂地拉罗司与去铁酮联合治疗输血依赖型地中海贫血患儿铁过载的疗效和安全性:一项前瞻性观察研究。
Indian J Pediatr. 2021 Apr;88(4):330-335. doi: 10.1007/s12098-020-03442-5. Epub 2020 Jul 13.
3
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.甲磺酸去铁胺用于治疗依赖输血的地中海贫血患者的输血性铁过载。
Cochrane Database Syst Rev. 2013 Aug 21;2013(8):CD004450. doi: 10.1002/14651858.CD004450.pub3.
4
The Correlation Between Iron Overload and Endocrine Function in Adult Transfusion-Dependent Beta-Thalassemia Patients with Growth Retardation.成年依赖输血的β地中海贫血生长发育迟缓患者铁过载与内分泌功能的相关性
J Blood Med. 2021 Aug 17;12:749-753. doi: 10.2147/JBM.S325096. eCollection 2021.
5
Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.不同铁螯合剂对埃及铁过载β地中海贫血患儿的治疗效果。
Infect Disord Drug Targets. 2015;15(2):98-105. doi: 10.2174/1871526515666150724111721.
6
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.去铁酮与地拉罗司治疗依赖输血的血红蛋白病儿科患者的疗效和安全性评估(DEEP-2):一项多中心、随机、开放标签、非劣效性3期试验。
Lancet Haematol. 2020 Jun;7(6):e469-e478. doi: 10.1016/S2352-3026(20)30100-9.
7
Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.口服铁螯合剂及其新型组合疗法治疗儿童地中海贫血的疗效和安全性比较
Indian Pediatr. 2016 Mar;53(3):207-10. doi: 10.1007/s13312-016-0821-4.
8
Drug utilization study and cost analysis of adult β-thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya.印度苏拉巴亚苏托莫综合医院成人重型β地中海贫血患者治疗的药物利用研究和成本分析。
J Basic Clin Physiol Pharmacol. 2021 Jun 25;32(4):611-616. doi: 10.1515/jbcpp-2020-0429.
9
Serum Zinc Level in β-Thalassemia Major: A Retrospective Study in Southwest Iran.重型β地中海贫血患者的血清锌水平:伊朗西南部的一项回顾性研究
Hemoglobin. 2021 Mar;45(2):103-106. doi: 10.1080/03630269.2021.1918149. Epub 2021 Apr 26.
10
Anthropometric measurements in children having transfusion-dependent beta thalassemia.对依赖输血的β地中海贫血患儿的人体测量
Hematology. 2018 May;23(4):248-252. doi: 10.1080/10245332.2017.1396044. Epub 2017 Oct 31.

引用本文的文献

1
[Monitoring and interventions of growth disorders and endocrine function in children with transfusion-dependent thalassemia].[输血依赖型地中海贫血患儿生长障碍及内分泌功能的监测与干预]
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Apr 15;27(4):389-394. doi: 10.7499/j.issn.1008-8830.2501080.

本文引用的文献

1
A Systematic Review and Meta-Analysis of Stature Growth Complications in β-thalassemia Major Patients.β-重型地中海贫血患者生长并发症的系统评价和荟萃分析。
Ann Glob Health. 2021 Jun 8;87(1):48. doi: 10.5334/aogh.3184.
2
Effectiveness of Deferasirox in Pediatric Thalassemia Patients: Experience from a Tertiary Care Hospital of Odisha.地拉罗司治疗小儿地中海贫血患者的有效性:来自奥里萨邦一家三级护理医院的经验。
Indian J Pharmacol. 2020 May-Jun;52(3):172-178. doi: 10.4103/ijp.IJP_68_18. Epub 2020 Aug 4.
3
Growth pattern in thalassemic children and their correlation with serum ferritin.地中海贫血患儿的生长模式及其与血清铁蛋白的相关性。
J Family Med Prim Care. 2020 Feb 28;9(2):1166-1169. doi: 10.4103/jfmpc.jfmpc_951_19. eCollection 2020 Feb.
4
PediTools Electronic Growth Chart Calculators: Applications in Clinical Care, Research, and Quality Improvement.儿科工具电子生长图表计算器:在临床护理、研究和质量改进中的应用。
J Med Internet Res. 2020 Jan 30;22(1):e16204. doi: 10.2196/16204.
5
Prevalence of growth and endocrine disorders in Malaysian children with transfusion-dependent thalassaemia.马来西亚依赖输血的地中海贫血儿童的生长和内分泌紊乱的患病率。
Singapore Med J. 2019 Jun;60(6):303-308. doi: 10.11622/smedj.2018155. Epub 2018 Dec 17.
6
Growth and Endocrine Function in Tunisian Thalassemia Major Patients.突尼斯重型地中海贫血患者的生长与内分泌功能
Mediterr J Hematol Infect Dis. 2018 May 1;10(1):e2018031. doi: 10.4084/MJHID.2018.031. eCollection 2018.
7
The effect of iron chelation therapy on overall survival in sickle cell disease and β-thalassemia: A systematic review.铁螯合疗法对镰状细胞病和β-地中海贫血患者总生存期的影响:系统评价。
Am J Hematol. 2018 Jul;93(7):943-952. doi: 10.1002/ajh.25103. Epub 2018 Apr 28.
8
Final adult height and endocrine complications in young adults with β-thalassemia major (TM) who received oral iron chelation (OIC) in comparison with those who did not use OIC.与未使用口服铁螯合剂(OIC)的重度β地中海贫血(TM)青年成人相比,接受口服铁螯合剂(OIC)的重度β地中海贫血(TM)青年成人的最终成人身高和内分泌并发症情况。
Acta Biomed. 2018 Feb 16;89(2-S):27-32. doi: 10.23750/abm.v89i2-S.7084.
9
Anthropometric measurements in children having transfusion-dependent beta thalassemia.对依赖输血的β地中海贫血患儿的人体测量
Hematology. 2018 May;23(4):248-252. doi: 10.1080/10245332.2017.1396044. Epub 2017 Oct 31.
10
Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.输血依赖型地中海贫血患者的铁螯合疗法:当前策略与未来方向
J Blood Med. 2015 Jun 17;6:197-209. doi: 10.2147/JBM.S72463. eCollection 2015.

血清铁蛋白与小儿输血依赖型地中海贫血生长状态的关系

Relationship between serum ferritin and growth status of pediatric transfusion dependent thalassemia.

作者信息

Cahyadi Andi, Ugrasena I Dewa Gede, Andarsini Mia Ratwita, Larasati Maria Christina Shanty, Jauhari Raden Muhammad Zulfan, Arumsari Diah Kusuma

机构信息

Department of Child Health, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Academic Hospital, Surabaya, East Java, Indonesia.

出版信息

Caspian J Intern Med. 2023 Summer;14(3):425-432. doi: 10.22088/cjim.14.3.425.

DOI:10.22088/cjim.14.3.425
PMID:37520873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10379800/
Abstract

BACKGROUND

Growth retardation is a long-term complication in pediatric transfusion-dependent thalassemias (TDTs), presented as short-stature and upper body segment shortening. The cause of this condition was chronic hypoxia, iron overload, endocrinopathy, inadequate transfusion, and iron chelation. We analyze the relationship between ferritin level and growth status of pediatric TDTs.

METHODS

This was a cross-sectional study on pediatric TDTs aged 2-18 years old at Dr. Soetomo General Academic Hospital Surabaya, Indonesia conducted in 2020. They required blood transfusion every 2-4 weeks. We evaluated the ratio of upper/lower body segments, weight for age Z-score (WAZ), height for age Z-score (HAZ), and body mass index (BMI) Z-score, based on CDC growth chart as growth status parameters. Serum ferritin was checked every three months to determine iron overload and iron chelation (deferiprone, deferasirox and deferoxamine). We used Spearman correlation and Mann-Whitney U test to analyze between variables (α=0.05).

RESULTS

We enrolled 15/29 males with median age 10.5 years. Serum Ferritin had negative correlation with the ratio of upper/lower body segments (rho=-0.552; P=0.002), but not for HAZ (rho=-0.078; P=0.694), WAZ (rho=-0.186; P=0.342), BMI Z-score (rho=-0.089; P=0.653) especially if serum ferritin was above 2500 µ/L. In deferiprone group (n=8), the WAZ (P=0.034) and BMI Z-score (P=0.031) were lower; but the ratio of upper/lower body segments was greater (P=0.039) than the deferasirox group.

CONCLUSION

Growth retardation was more visible in pediatric TDTs with high ferritin and in deferiprone group. The height and the ratio of upper/lower body segments of the body were more affected.

摘要

背景

生长发育迟缓是小儿输血依赖型地中海贫血(TDT)的一种长期并发症,表现为身材矮小和上身段缩短。这种情况的原因是慢性缺氧、铁过载、内分泌病、输血不足以及铁螯合作用。我们分析了小儿TDT患者铁蛋白水平与生长状况之间的关系。

方法

这是一项于2020年在印度尼西亚泗水苏托莫综合学术医院对2至18岁小儿TDT患者进行的横断面研究。他们每2至4周需要输血一次。我们根据美国疾病控制与预防中心(CDC)生长图表评估上身段与下身段的比例、年龄别体重Z评分(WAZ)、年龄别身高Z评分(HAZ)和体重指数(BMI)Z评分,将其作为生长状况参数。每三个月检查一次血清铁蛋白,以确定铁过载和铁螯合情况(去铁酮、地拉罗司和去铁胺)。我们使用Spearman相关性分析和Mann-Whitney U检验来分析变量之间的关系(α=0.05)。

结果

我们纳入了15名男性/29名患者,中位年龄为10.5岁。血清铁蛋白与上身段与下身段的比例呈负相关(rho=-0.552;P=0.002),但与HAZ(rho=-0.078;P=0.694)、WAZ(rho=-0.186;P=0.342)、BMI Z评分(rho=-0.089;P=0.653)无相关性,尤其是当血清铁蛋白高于2500µ/L时。在去铁酮组(n=8)中,WAZ(P=0.034)和BMI Z评分(P=0.031)较低;但上身段与下身段的比例高于地拉罗司组(P=0.039)。

结论

在铁蛋白水平高的小儿TDT患者和去铁酮组中,生长发育迟缓更为明显。身高和上身段与下身段的比例受影响更大。